| David C Leppla, MD | |
|
5590 Kietzke Ln, Reno, NV 89511-3019 | |
| (775) 323-2080 | |
| (775) 325-2334 |
| Full Name | David C Leppla |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 31 Years |
| Location | 5590 Kietzke Ln, Reno, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477508018 | NPI | - | NPPES |
| 100505678 | Medicaid | NV | |
| CC7599 | Other | NV | BLUE CROSS BLUE SHIELD |
| 880167036A023 | Other | NV | TRICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 11236 (Nevada) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Berkshire Medical Center | Pittsfield, MA | Hospital |
| Fairview Hospital | Great barrington, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Berkshire Faculty Services Inc | 8224068424 | 222 |
News Archive
Nearly half of all birth defects involve the face and skull and, for the most part, scientists remain unclear as to why most occur. To better serve families at risk for these conditions, scientists need a comprehensive and systematic understanding of how the faces of healthy children form and what goes wrong to cause common malformations, such as cleft lip and palate.
Peripheral arterial disease is a common circulation problem in which reduced blood flow can lead to complications that jeopardize the limbs, possibly even requiring amputation. Procedures known as revascularization have reduced the need for amputations 40 percent over two decades, Mayo Clinic research shows.
Using new, highly sensitive genomic sequencing technology, an international team of researchers has found new biological evidence to help explain why the malaria vaccine candidate RTS,S/AS01 (called RTS,S) provided only moderate protection among vaccinated children during clinical testing.
Pervasis Therapeutics, Inc. today announced that it completed the initial closing of a $17 million third round of financing. The proceeds will be used primarily to support the company's ongoing clinical development programs, including PVS-10200, a biologically active therapy designed to reestablish healthy vasculature following common interventions to treat peripheral arterial disease (PAD) and potentially other conditions.
Before patients receive intravenous antimicrobial infusion therapy outside of the hospital - whether at home, a doctor's office or a skilled nursing facility - an infectious diseases specialist should review the order to ensure the most appropriate treatment, suggest updated guidelines released by the Infectious Diseases Society of America.
› Verified 6 days ago
| Entity Name | Berkshire Faculty Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548212939 PECOS PAC ID: 8224068424 Enrollment ID: O20050817001122 |
News Archive
Nearly half of all birth defects involve the face and skull and, for the most part, scientists remain unclear as to why most occur. To better serve families at risk for these conditions, scientists need a comprehensive and systematic understanding of how the faces of healthy children form and what goes wrong to cause common malformations, such as cleft lip and palate.
Peripheral arterial disease is a common circulation problem in which reduced blood flow can lead to complications that jeopardize the limbs, possibly even requiring amputation. Procedures known as revascularization have reduced the need for amputations 40 percent over two decades, Mayo Clinic research shows.
Using new, highly sensitive genomic sequencing technology, an international team of researchers has found new biological evidence to help explain why the malaria vaccine candidate RTS,S/AS01 (called RTS,S) provided only moderate protection among vaccinated children during clinical testing.
Pervasis Therapeutics, Inc. today announced that it completed the initial closing of a $17 million third round of financing. The proceeds will be used primarily to support the company's ongoing clinical development programs, including PVS-10200, a biologically active therapy designed to reestablish healthy vasculature following common interventions to treat peripheral arterial disease (PAD) and potentially other conditions.
Before patients receive intravenous antimicrobial infusion therapy outside of the hospital - whether at home, a doctor's office or a skilled nursing facility - an infectious diseases specialist should review the order to ensure the most appropriate treatment, suggest updated guidelines released by the Infectious Diseases Society of America.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David C Leppla, MD 5590 Kietzke Ln, Reno, NV 89511-3019 Ph: (775) 323-2080 | David C Leppla, MD 5590 Kietzke Ln, Reno, NV 89511-3019 Ph: (775) 323-2080 |
News Archive
Nearly half of all birth defects involve the face and skull and, for the most part, scientists remain unclear as to why most occur. To better serve families at risk for these conditions, scientists need a comprehensive and systematic understanding of how the faces of healthy children form and what goes wrong to cause common malformations, such as cleft lip and palate.
Peripheral arterial disease is a common circulation problem in which reduced blood flow can lead to complications that jeopardize the limbs, possibly even requiring amputation. Procedures known as revascularization have reduced the need for amputations 40 percent over two decades, Mayo Clinic research shows.
Using new, highly sensitive genomic sequencing technology, an international team of researchers has found new biological evidence to help explain why the malaria vaccine candidate RTS,S/AS01 (called RTS,S) provided only moderate protection among vaccinated children during clinical testing.
Pervasis Therapeutics, Inc. today announced that it completed the initial closing of a $17 million third round of financing. The proceeds will be used primarily to support the company's ongoing clinical development programs, including PVS-10200, a biologically active therapy designed to reestablish healthy vasculature following common interventions to treat peripheral arterial disease (PAD) and potentially other conditions.
Before patients receive intravenous antimicrobial infusion therapy outside of the hospital - whether at home, a doctor's office or a skilled nursing facility - an infectious diseases specialist should review the order to ensure the most appropriate treatment, suggest updated guidelines released by the Infectious Diseases Society of America.
› Verified 6 days ago
Joseph R Walker, M.D. Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 5590 Kietzke Ln, Reno, NV 89511 Phone: 775-323-2080 Fax: 775-325-2334 | |
Jay K Morgan, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 5590 Kietzke Ln, Reno, NV 89511 Phone: 775-323-2080 Fax: 775-323-8216 | |
Michael H Song, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 343 Elm St, Suite 202, Reno, NV 89503 Phone: 775-323-6100 Fax: 775-323-6118 | |
John S Davis, M.D. Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 5590 Kietzke Ln, Reno, NV 89511 Phone: 775-323-2080 Fax: 775-325-2334 | |
William N Dawson Jr., M.D. Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 130 Southridge Dr, Reno, NV 89509 Phone: 775-329-4124 | |
Dr. Michael Kevin Moore, M.D., M.S. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 5590 Kietzke Ln, Reno, NV 89511 Phone: 775-323-2080 Fax: 775-323-8216 | |
Christopher Demers, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 5590 Kietzke Ln, Reno, NV 89511 Phone: 775-323-2080 Fax: 775-323-8216 |